Anglo-Swedish drug company AstraZeneca has announced that it will get rid of its R&D president Martin Mackay in a bid to replace his position with three different R&D roles.
The drug giant said on 15 January that the move would “increase the representation of the company’s scientific expertise” in the senior management team. It also confirmed that Mackay would have to leave the firm by the end of the month.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.